Kezar Life Sciences Inc.
05/21/2026 | Press release | Distributed by Public on 05/21/2026 04:04
Termination Notice (Form 15-12G)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
001-38543
Commission File Number
KEZAR LIFE SCIENCES, INC.
(Exact name of registrant as specified in its charter)
4000 Shoreline Court, Suite 300
South San Francisco, CA 94080
(650) 822-5600
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)
Common Stock, $0.001 par value per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
Rule 12g-4(a)(1)
|
☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) Rule 15d-6 | ☐ |
| Rule 15d-22(b) | ☐ |
|
|
Approximate number of holders of record as of the certification or notice date: | One |
Pursuant to the requirements of the Securities Exchange Act of 1934, Kezar Life Sciences, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
|
Date: May 21, 2026
|
KEZAR LIFE SCIENCES, INC.
|
|
|
By:
|
/s/ Michael Hearne
|
|
|
|
Name: Michael Hearne
|
|
|
|
Title: Chief Financial Officer
|
|
Kezar Life Sciences Inc. published this content on May 21, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 21, 2026 at 10:05 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]